Alpha-Ketoglutarate with TGFβ/HIF1α Blocker May Improve Lung Scarring in Mice with Severe COVID-19

Approximately 10% of COVID-19 survivors worldwide experience pulmonary fibrosis and acute respiratory distress syndrome (ARDS).

• Pulmonary fibrosis and ARDS are significant challenges for patients with post-acute sequelae of COVID-19 (PASC).
• PASC is associated with impaired respiratory function and long-term health issues in survivors.
• Recent WHO reports from 83 countries highlight severe morbidity linked to PASC among COVID-19 survivors.
• A mouse model was developed to study the disease mechanisms related to PASC.
• The research focused on identifying signalling molecules to inform potential targeted treatment strategies.

Simplified